Biologics manufacturing facility
In April 2018, China-based biologics services provider WuXi Biologics announced its plans to construct a new biologics drug substance manufacturing facility in Dundalk, Ireland.
Estimated to cost more than €325m ($394m), the new biologics manufacturing facility is expected to create 400 new jobs over five years and 700 jobs during the construction phase.
The new facility will be Wuxi Biologics’ first site outside of China and is expected to help accelerate the development of biologics in Europe.
The new manufacturing facility will be built on a 26ha green-field site owned by Ireland’s Industrial Development Authority (IDA) in Mullagharlin, Dundalk, Ireland.
Dundalk was selected due to the IDA’s strong endorsement of regional and property strategy. The IDA has been supporting the development of biopharmaceutical and knowledge-based facilities by obtaining pre-approved planning for key sites located in the region.
WuXi’s manufacturing facility will add to the growing cluster of biopharmaceutical companies in the midland and western region of Ireland.
The state-of-the-art manufacturing facility is one of the first and largest green-field pharmaceutical projects by a Chinese company in Ireland. It will feature single-use bioreactors for commercial bio-manufacturing and be equipped with next-generation processing technology.
The facility will be installed with 48,000l fed-batch bioreactors and 6,000l perfusion bioreactors. It will be one of the world’s largest facilities equipped with disposable bioreactors.
WuXi Biologics will work with local partners to build the new facility.
The project is supported by the Irish Government through the IDA and Ireland Strategic Investment Fund (ISIF), a sovereign development fund managed by National Treasury Management Agency (NTMA).
The new facility is part of WuXi’s business model, which aims to increase customer demand for its products as they move from development to commercialisation.
The facility will enable WuXi to expand its commercial manufacturing capacities and strengthen its global integrated solution platform.
It will also help towards the Irish Government’s goal of increasing investment and jobs in the region by more than 40% under the Regional Action Plans for Jobs initiative.
Wuxi Biologics is an affiliate of WuXi AppTec that offers biologics platforms for the discovery and development of biologics from concept to commercial manufacturing to clients worldwide. Along with the parent company, it provides a single source contract development solution to clients globally.
The company’s three facilities in Wuxi city, Shanghai and Suzhou offer an open-access technology platform for the commercialisation of biologic drugs. WuXi also opened a bio-manufacturing facility in Philadelphia in 2015.
In addition to the Dundalk facility, WuXi is developing a new research and development (R&D) centre in Shanghai, China, through its subsidiary WuXi STA.
The subsidiary entered an agreement with the Shanghai Jinshan District for the construction of the facility, in April 2018.
Alnylam Pharmaceuticals is constructing a new drug substance manufacturing and cGMP warehouse facility in Norton, Massachusetts, US. The company broke…
Neopharma opened a pharmaceutical plant in Abu Dhabi, United Arab Emirates, in July 2003. The plant then entered a three-month…
French pharmaceutical company Sanofi’s manufacturing plant in Goa, India, is located in the Verna Industrial Park, owned by Sanofi’s Indian…
GlaxoSmithKline (GSK) began construction of an oral solid-dose manufacturing plant at the Vemgal Industrial Area in India in September 2015.…